KWM
BNTX icon

Kingsview Wealth Management’s BioNTech BNTX Stock Holding History

Kingsview Wealth Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,675
Closed -$432K – 874
2021
Q4 		$432K Sell
1,675
-1,193
-42% -$327K 0.02% 622
2021
Q3 		$783K Buy
+2,868
New +$912K 0.04% 441

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Kingsview Wealth Management's BNTX Position: Q1 2022 in Review

Kingsview Wealth Management sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 1,675 shares — an estimated $432K sold.

Kingsview Wealth Management first reported a position in BNTX in Q3 2021 and held it in 2 quarters. The position peaked at $783K in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

  • Kingsview Wealth Management reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
  • Kingsview Wealth Management sold 1,675 BioNTech shares in Q1 2022, an estimated $432K.
  • Kingsview Wealth Management first reported a position in BioNTech in Q3 2021 and held it in 2 quarters.
  • Kingsview Wealth Management's BioNTech position peaked at $783K in Q3 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Kingsview Wealth Management's 13F filing for Q1 2022, filed 8 Feb 2024.